EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX

Barbora Puzderova, Petra Belvoncikova, Katarina Grossmannova, Lucia Csaderova, Martina Labudova iD, Silvia Fecikova, Jaromir Pastorek, Monika Barathova

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241311094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Barbora Puzderova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia. Hauptthemen laut MEDLINE: Propranolol, Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research & Developmental Support Agency, Slovak Scientific Grant Agency, Operational Programme Integrated Infrastructure for the project: Integrative strategy in devel-opment of personalized medicine of selected malignant tumors and….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to chemotherapy represents a persisting medical problem, ranking among main causes of chemotherapy failure and cancer mortality. There is a possibility to utilize and repurpose already existing therapeutics which were not primarily intended for oncological treatment. Overactivation of adrenergic receptors and signaling dysregulation promotes tumor progression, metastatic potential, immune system evasion, tumor angiogenesis and drug resistance. The non-selective beta-blocker propranolol, approved in infantile haemangioma treatment, has a high potential for use in cancer therapy. We analyzed the effects of propranolol and 5-fluorouracil combination on sensitive and resistant cells derived from colorectal carcinoma in monolayers, single-component and co-culture spheroids and in vivo mouse models. Our results revealed that propranolol is able to exert its effect not only in chemosensitive colorectal cells, but also in 5-fluorouracil resistant cells. Propranolol disrupts the hypoxic adaptation machinery by inhibiting HIF1α, carbonic anhydrase IX, and activates apoptosis, which may be important in the management of chemo-resistant patients. We showed that propranolol slows down the growth of xenografts formed from colorectal cancer cells, even from cells already adapted to the β-blocker. We provide clear evidence that blockade of β-adrenergic receptors affects essential signaling pathways modulating tumor microenvironment and thus the response to anticancer therapy. Our findings indicate that propranolol could be repurposed to serve as chemosensitizer in combined therapy aimed at disrupting homeostasis of tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropranololNeoplasmsHumansAnimalsMiceCarbonic Anhydrase IXTumor MicroenvironmentAntigens, NeoplasmFluorouracilCell Line, Tumor

Stichwörter der Autor:innen

carbonic anhydrase IXchemoresistancehypoxiahypoxia inducible factor 1propranololtumor microenvironment

Substanzen

Carbonic Anhydrase IXPropranololAntigens, NeoplasmFluorouracil

Autor:innen und Institutionen

  • Biomedical Research Center, Institute of Virology, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.
  • National Institute of Lung Disaeses, Thorax Surgery and Tuberculosis, Vyšné Hágy 1, 059 84 Vysoké Tatry, Slovakia.
  • Mabpro, a.s., Dubravska Cesta 2, 841 04 Bratislava, Slovakia.

ORCID-Profile: Martina Labudova

Förderung

  • Research & Developmental Support Agency
  • Slovak Scientific Grant Agency
  • Operational Programme Integrated Infrastructure for the project: Integrative strategy in devel-opment of personalized medicine of selected malignant tumors and…
  • Research & Developmental Support Agency
  • Operational Programme Integrated Infrastructure for the project: Integrative strategy in development of personalized medicine of selected malignant tumors and…

Zitieren

APA

Puzderova, B., Belvoncikova, P., Grossmannova, K., Csaderova, L., Labudova, M., Fecikova, S., Pastorek, J., & Barathova, M. (2023). Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241311094

Vancouver

Puzderova B, Belvoncikova P, Grossmannova K, Csaderova L, Labudova M, Fecikova S, et al. Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241311094

BibTeX
@article{Puzderova2023,
  author = {Puzderova, Barbora and Belvoncikova, Petra and Grossmannova, Katarina and Csaderova, Lucia and Labudova, Martina and Fecikova, Silvia and Pastorek, Jaromir and Barathova, Monika},
  title = {Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241311094}
}
Kostenlos starten →